Anacor Pharmaceuticals

Anacor has discovered and is developing five clinical compounds, including its three lead programs: AN2690, a topical antifungal for the treatment of onychomycosis; AN2728, a topical anti-inflammatory PDE-4 inhibitor for the treatment of psoriasis; and GSK 2251052, or GSK '052 (formerly referred to as AN3365), a systemic antibiotic for the treatment of infections caused by Gram-negative bacteria, which has been licensed to GlaxoSmithKline under the companies' research and development agreement. In addition, Anacor is developing AN2718 as a topical antifungal product candidate for the treatment of onychomycosis and skin fungal infections, and AN2898 as a topical anti-inflammatory product candidate for the treatment of psoriasis and atopic dermatitis.

Type
Public
HQ
Palo Alto, US
Founded
2002
Size (employees)
110 (est)
Website
anacor.com
Anacor Pharmaceuticals was founded in 2002 and is headquartered in Palo Alto, US

Anacor Pharmaceuticals Office Locations

Anacor Pharmaceuticals has an office in Palo Alto
Palo Alto, US (HQ)
1020 E Meadow Cir

Anacor Pharmaceuticals Metrics

Anacor Pharmaceuticals Financial Metrics

Revenue (2015)

$82.4 m

Revenue growth (2014-15), %

298%

Gross profit

$78.3 m

Gross profit margin (2015), %

95%

Net income (2015)

($61.2 m)

Cash (31-Dec-2015)

$53.7 m
Anacor Pharmaceuticals's revenue was reported to be $82.4 m in FY, 2015 which is a 298.1% increase from the previous period.
FY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015

Revenue

$17.2 m$20.7 m$82.4 m

Revenue growth, %

20%298%

Cost of goods sold

$797 k$4 m

Gross profit

$19.9 m$78.3 m

Gross profit Margin, %

96%95%

Operating expense total

($75.3 m)$111.5 m$138.7 m

EBIT

$92.5 m($90.8 m)($56.4 m)

EBIT margin, %

537%(439%)(68%)

Interest expense

$2 m$1.4 m$2.9 m$4.1 m$4.7 m$5.5 m

Interest income

$55 k$647 k

Pre tax profit

($61.2 m)

Income tax expense

$1.7 m($10.3 m)($10.3 m)

Net Income

$84.8 m($87.1 m)($61.2 m)
Y, 2009Y, 2010Y, 2011Y, 2012Y, 2013Y, 2014Y, 2015

Cash

$8.6 m$21.7 m$15.2 m$10.3 m$114.8 m$16 m$53.7 m

Accounts Receivable

Inventories

$2.3 m$6.5 m

Current Assets

$155.4 m$170.1 m

PP&E

$1.5 m$2.3 m

Total Assets

$172.2 m$176.1 m

Accounts Payable

$4.7 m$5.8 m

Current Liabilities

$16.2 m$29.5 m

Additional Paid-in Capital

$251.8 m$331.1 m

Retained Earnings

($130.4 m)($278.8 m)

Total Equity

$121.4 m$52.3 m

Financial Leverage

1.4 x3.4 x
FY, 2013FY, 2014FY, 2015

Net Income

$84.8 m($87.1 m)($61.2 m)

Depreciation and Amortization

$507 k$499 k$629 k

Accounts Receivable

Inventories

($2.4 m)($2.2 m)

Accounts Payable

$1.7 m($188 k)$758 k

Cash From Operating Activities

$90.1 m($39.3 m)($56.3 m)

Purchases of PP&E

($450 k)($683 k)($811 k)

Cash From Investing Activities

($17.5 m)($125.6 m)$83 m

Short-term Borrowings

($25.7 m)($30 m)($30 m)

Anacor Pharmaceuticals Company Life

You may also be interested in